Are there clinical trials combining immunotherapy with other treatments for Prostate Cancer

Clinical Trials Combining Immunotherapy with Other Treatments for Prostate Cancer

Yes, there are several clinical trials exploring combinations of immunotherapy with other treatments for prostate cancer. This is actually an important area of research because, as experts explain, immunotherapy combinations are likely to be more effective than single-agent treatments.

Why Combinations Matter

According to recent expert discussions on immunotherapy for metastatic castrate-resistant prostate cancer, immunotherapies should be considered in combinations with other therapies rather than used alone. Here's why:

Prostate cancer is what researchers call an "immunologically cold" tumor, meaning it has very few T-cells (immune cells that kill cancer) naturally present in the tumor microenvironment. Additionally, prostate cancer contains many immunosuppressive myeloid cells (bad immune cells that help the cancer hide from the immune system). This makes single-drug approaches less effective.

Current Combination Approaches Being Studied

1. T-cell Bispecifics + Immune Checkpoint Inhibitors The emerging backbone of immunotherapy for prostate cancer will likely be T-cell bispecifics (drugs that bring T-cells directly to cancer cells) combined with checkpoint inhibitors like anti-PD-1 therapies (such as pembrolizumab/Keytruda). These combinations aim to work together to enhance immune response.

2. Immunotherapy + Radiation Therapy Researchers are investigating how to combine radiation with immunotherapies. The theory is that lower-dose radiation may preserve some good immune cells while still damaging cancer, allowing immunotherapy to work more effectively. There was a Phase 3 trial combining ipilimumab (an immune checkpoint inhibitor) with radiation that showed promise, though it narrowly missed its primary endpoint.

3. Immunotherapy + Chemotherapy Combinations of immunotherapy with chemotherapy drugs like docetaxel are being explored in clinical trials.

4. Bipolar Androgen Therapy (BAT) + Immunotherapy In the COMBAT trial, BAT (cycling testosterone levels) was combined with nivolumab (an immune checkpoint inhibitor), achieving a 40% PSA response rate and 24% RECIST response rate (percentage of patients whose cancer shrank).

5. Adaptive Design Trials These are innovative trial designs that allow modifications during the trial. For example, all patients might start with one immunotherapy (like PD-1 inhibitor), and responders continue while non-responders have additional therapies added (like vaccines). This helps identify who actually needs combination therapy versus single-agent treatment.

Biomarker-Guided Selection

An important development is using biomarkers to predict who will respond to which combinations:

• MSI-High (Microsatellite Instability High): Patients with MSI-high prostate cancer have shown approximately 50% response rates to anti-PD-1 therapy alone, though only about 25% achieve durable long-term responses. These patients may benefit from combination approaches to improve that durable response rate.

• Tumor Immune Profiling: Tests like those from BostonGene use whole exome sequencing and RNA analysis to determine if your tumor is "immune-rich non-fibrotic" (more likely to respond to immunotherapy) or "immune-rich fibrotic" (less likely to respond to anti-PD-1 alone, better suited for combinations).

Finding Clinical Trials

To locate specific trials you may be eligible for:

1. Visit ClinicalTrials.gov and search for "prostate cancer immunotherapy" along with your specific disease stage
2. Ask your oncologist which combination trials are open at your treatment center
3. Contact major cancer centers like MD Anderson, Memorial Sloan Kettering, or UCSF, which are actively enrolling patients in immunotherapy combination studies

Important Considerations

According to experts in the field, most clinicians are still cautious about immunotherapies in prostate cancer because they want evidence from Phase III trials (large, rigorous studies). However, work is ongoing to improve how immunotherapies are combined and sequenced.

One key point: if you're considering a single immunotherapy like Keytruda and it doesn't work, this may exclude you from some combination trials (with the exception of Provenge). This is why discussing combination approaches upfront with your oncologist is important.

Questions to Ask Your Oncologist

1. Are there combination immunotherapy trials I'm eligible for based on my specific tumor characteristics?
2. Should I get biomarker testing (like MSI or tumor immune profiling) to guide which combinations might work best for me?
3. What is the evidence for combining [specific therapy] with immunotherapy in my situation?
4. If I start one immunotherapy and it doesn't work, what combination options would still be available to me?
5. Are there adaptive design trials open that could adjust my treatment based on how I respond?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.